Max Rosett, serving as the Chief Financial Officer for Immunome Inc. (NASDAQ: IMNM), executed a transaction involving the sale of 60,000 shares of the company's common stock on June 15, 2026. The aggregate value of these shares reached $1,093,800. The execution occurred within a price band of $17.95 to $18.66 per share, resulting in a weighted average sale price of $18.23. This disposition was facilitated under a Rule 10b5-1 trading plan, a mechanism Mr. Rosett established on December 26, 2025, to automate equity transactions.
Concurrent with the sale, Mr. Rosett acquired an equivalent quantity of 60,000 shares through the exercise of fully vested stock options on the same date. The exercise price for these options was set at $1.05 per share, establishing an acquisition cost of $63,000. Following the completion of these simultaneous transactions, Mr. Rosett's direct holding in Immunome common stock stands at 54,037 shares.
The executive's activity follows a period of substantial share price appreciation for Immunome. Data indicates the stock has delivered a 100% return over the trailing twelve months. As of the reporting period, the shares were trading at $18.51. Market analysis suggests that the current valuation may be slightly extended relative to fundamental metrics. Furthermore, the platform notes that the stock exhibits significant price volatility, a characteristic that often prompts executives to utilize pre-arranged plans to secure gains during periods of elevated price action.
Insider activity occurs as Immunome advances critical clinical milestones. The company recently announced the dosing of the first patient in a Phase 1 trial for IM-1617, an antibody-drug conjugate targeting solid tumors. This program leverages Immunome's proprietary HC74 inhibitor to evaluate safety and efficacy. Additionally, the company presented data from its Phase 3 RINGSIDE trial for varegacestat, a therapy for desmoid tumors. The results demonstrated an 84% reduction in the risk of disease progression or death compared to a placebo. Following these outcomes, Immunome submitted a New Drug Application to the U.S. Food and Drug Administration for varegacestat.
Wall Street response has been constructive. Truist Securities raised its price target for Immunome to $37, maintaining a Buy rating, citing the potential market impact of the drug. Barclays initiated coverage with an overweight rating and a $36 price target, highlighting the company's focus on antibody-drug conjugate therapeutics and the potential commercial launch of varegacestat. These developments underscore the company's strategic position in advancing oncology treatments.